ReviewClinical ophthalmology (Auckland, N.Z.)2016
Limbal stem cell transplantation: current perspectives.
Review in Clinical ophthalmology (Auckland, N.Z.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 83 citations in OpenAlex.
- Cellularized Skin Substitute Bioengineering for Regenerative Medicine: Cell Sources, Culture Strategies, and Transition Toward Defined, Xeno-Free Culture Systems.Advanced healthcare materials · 2026Review
- Wireless image transfer across opaque cornea: A novel approach to visual rehabilitation.Indian journal of ophthalmology · 2026Article
- Multimodal objective assessment of a porcine limbal stem cell deficiency model for corneal therapy research.Scientific reports · 2025Article
- Limbal stem cell sheet bandage for short-term treatment of corneal regeneration.BMC ophthalmology · 2025Article
- Cosmetic Therapeutic Keratopigmentation.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Clinical Outcomes and Early Postoperative Complications in Boston Type I Keratoprosthesis Implantation: A Retrospective Study.Journal of clinical medicine · 2024Article
- Targeting limbal epithelial stem cells: master conductors of corneal epithelial regeneration from the bench to multilevel theranostics.Journal of translational medicine · 2024Review
- Available Therapeutic Options for Corneal Neovascularization: A Review.International journal of molecular sciences · 2024Review
- New characterization and safety evaluation of human limbal stem cells used in clinical application: fidelity of mitotic process and mitotic spindle morphologies.Stem cell research & therapy · 2023Article
- In Vivo Confocal Microscopy in Limbal Stem Cell Deficiency After Mesenchymal Stem Cell Transplantation: A Sub-analysis from a Phase I-II Clinical Trial.Ophthalmology and therapy · 2023Article
- Ocular-Surface Regeneration Therapies for Eye Disorders: The State of the Art.Biotech (Basel (Switzerland)) · 2023Review
- Concise Review: Bioengineering of Limbal Stem Cell Niche.Bioengineering (Basel, Switzerland) · 2023Review
- The immunology of corneal limbal stem cells: the up-to-date approach to stem cell transplantation.Central-European journal of immunology · 2023Review
- Review
- Article
- Substance P/neurokinin-1 receptor pathway blockade ameliorates limbal stem cell deficiency by modulating mTOR pathway and preventing cell senescence.Stem cell reports · 2022Article
- Ocular Surface Preparation Before Keratoprosthesis Implantation.Ophthalmology and therapy · 2022Article
- Effect of Covid-19 on Eye Banks and Corneal Transplantations: Current Perspectives.Clinical ophthalmology (Auckland, N.Z.) · 2022Review
- A Review of the Diagnosis and Treatment of Limbal Stem Cell Deficiency.Frontiers in medicine · 2022Review
- Biofabrication of Artificial Stem Cell Niches in the Anterior Ocular Segment.Bioengineering (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Regeneration of the corneal surface after an epithelial insult involves division, migration, and maturation of a specialized group of stem cells located in the limbus. Several insults, both intrinsic and extrinsic, can precipitate destruction of the delicate microenvironment of these cells, resulting in limbal stem cell deficiency (LSCD). In such cases, reepithelialization fails and conjunctival epithelium extends across the limbus, leading to vascularization, persistent epithelial defects, and chronic inflammation. In partial LSCD, conjunctival epitheliectomy, coupled with amniotic membrane transplantation, could be sufficient to restore a healthy surface. In more severe cases and in total LSCD, stem cell transplantation is currently the best curative option. Before any attempts are considered to perform a limbal stem cell transplantation procedure, the ocular surface must be optimized by controlling causative factors and comorbid conditions. These factors include adequate eyelid function or exposure, control of the ocular surface inflammatory status, and a well-lubricated ocular surface. In cases of unilateral LSCD, stem cells can be obtained from the contralateral eye. Newer techniques aim at expanding cells in vitro or in vivo in order to decrease the need for large limbal resection that may jeopardize the "healthy" eye. Patients with bilateral disease can be treated using allogeneic tissue in combination with systemic immunosuppressive therapy. Another emerging option for this subset of patients is the use of noncorneal cells such as mucosal grafts. Finally, the use of keratoprosthesis is reserved for patients who are not candidates for any of the aforementioned options, wherein the choice of the type of keratoprosthesis depends on the severity of the disease. In summary, limbal stem cell transplantation improves both vision and quality-of-life in patients with ocular surface disorders associated with LSCD, and overall, the use of autologous tissue offers the best results. Future studies aim at improving cellular expansion and finding different sources of stem cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.